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bstract
The ubiquitin-proteasome system (UPS) maintains the integrity of cellular processes by controlling protein degradation pathways. The
ole of the UPS in proliferation, cell cycle, differentiation, DNA repair, protein folding, and apoptosis is well documented, and a wide range
f protein activities in these signaling pathways can be manipulated by UPS inhibitors, which include many anti-cancer agents. Naturally
ccurring and synthetic drugs designed to target the UPS are currently used for hematological cancers, including lymphoma. These drugs
argely interfere with the E1 and E2 regions of the 26S proteasome, blocking proteasomal activity and promoting apoptosis by enhancing
ctivities of the extrinsic (death receptors, Trail, Fas) and intrinsic (caspases, Bax, Bcl2, p53, nuclear factor-kappa B, p27) cell death programs.
his review focuses on recent clinical developments concerning UPS inhibitors, signaling pathways that are affected by down-regulation of
PS activities, and apoptotic mechanisms promoted by drugs in this class that are used to treat lymphoma.
 2013 Elsevier Ireland Ltd. 
omib; M
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.  Introduction
The homeostasis of cellular proteins is important for
aintaining the integrity and health of the cell, and active
rotein degradation by the ubiquitin-proteasome system
UPS) is the major pathway through which this cellular
alance is achieved (Fig. 1). This process is pivotal in
K.S. Suh et al. / Critical Reviews in Oncology/Hematology 87 (2013) 306–322 307
way by
c
d
d
a
r
a
(
e
f
a
t
t
2
t
u
c
p
t
g
o
E
s
t
a
t
t
c
r
p
f
i
p
c
p
t
p
t
c
m
r
g
m
c
o
a
s
i
a
a
m
[
t
s
r
iFig. 1. Protein degradation path
ell cycle control, transcriptional regulation, signal trans-
uction, antigen presentation, inflammation, ER-mediated
egradation, membrane trafficking, receptor endocytosis,
poptosis, and development [1–4]. Ubiquitin (Ub), a 76-
esidue protein, is attached to substrate proteins via  multiple
denosine-5′-triphosphate (ATP)-dependent processes by E1
Ub-activating), E2 (Ub-conjugating), and E3 (Ub-ligating)
nzymes. These enzymes act in harmoniously coordinated
ashion via  the ubiquitin moiety to achieve specific targeting
nd regulation of oligomerization, degradation, and post-
ranslational modification [5]. Proteasomes are abundant in
he cytosol, and consist of multiple proteins that form the
0S and 19S subcomponent complexes. Proteasomal pro-
ein degradation generally requires polyubiquitination, and
biquitinated proteins are first recognized by the 19S cap
omplex, which unfolds the substrate in an ATP-dependent
rocess and translocates it into the proteolytic chamber of
he 20S complex to be degraded [6]. The ubiquitin conju-
ation cascade begins with activation of the carboxyl group
f Gly-76 of ubiquitin by E1. Activated ubiquitin binds to
1 and is transferred to a Cys residue of E2, which either
ingly or in cooperation with E3 shuttles ubiquitin to a pro-
ein substrate. Subsequently, different combinations of E2
nd E3 enzymes add a polyubiquitin chain to provide selec-
ive tagging for degradation (Fig. 1). This process is used
o degrade misfolded or aged proteins, to regulate the cell
ycle through cyclin degradation, and to promote immune
esponses through antigenic peptide processing. Thus, com-
onents of the UPS pathway are attractive molecular targets
or therapeutic intervention. For a variety of reasons, most
w
c
f ubiquitin-proteasome system.
nhibitors that have been developed directly target the 20S
roteasome.
The UPS plays an important role in regulating the cell
ycle. Proteins such as cyclins A, B, D, and E, CDK inhibitor
27, p21, transcription factor E2F, retinoblastoma (Rb), and
umor suppressor p53 are regulated by proteasome-mediated
roteolysis. The blockage of cell cycle progression with pro-
easome inhibitors is currently used against various forms of
ancer. NF-B, which participates in immune and inflam-
atory responses, apoptosis, and cell proliferation, is also
egulated by the UPS. UPS-mediated protein degradation also
enerates antigenic peptides for presentation on MHC class I
olecules [7]. Consistent with this function, the aldehyde
lass of proteasome inhibitors partly inhibits presentation
f antigenic peptides [8]. The UPS is also manipulated
nd co-opted by certain viruses, including avian leuko-
is virus, human immunodeficiency virus type 1, simian
mmunodeficiency virus, Moloney murine leukemia virus,
nd Epstein–Barr virus [9–11]. UPS is also involved in viral
ssembly; proteolytic viral maturation is inhibited upon treat-
ent of infected cells with proteasome-specific inhibitors
12,13]. Proteasome inhibitors are broadly categorized into
wo groups (synthetic analogs and natural products), and their
tructural properties and mechanisms of action have been
eviewed in detail.
Given the importance of proteasomal protein degradation
n various intracellular processes, inhibitors of this pathway
ill continue to serve as both molecular probes of major
ellular networks as well as potential therapeutic agents
or various human diseases [14]. This review focuses on
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roteasome inhibitory mechanisms that are related to the
reatment of lymphoma, detailing current preclinical and clin-
cal developments and describing apoptotic mechanisms that
ay underlie the antitumor activities of the inhibitors.
.  Signaling  pathways  regulated  by  the  UPS
Numerous regulatory protein participants in cellular
rocesses undergo proteolytic degradation. The UPS has
een targeted as part of the chemotherapeutic regimen
or solid tumors and hematological malignancies, such as
on-Hodgkin’s lymphoma (NHL). The roles of proteins or
olecular targets that are proteolytically degraded by the 26S
roteasome of the UPS in basic cellular activities (Fig. 1), in
ymphomagenesis, and in tumor progression are described
elow.
Cell cycle progression requires programmed and peri-
dic expression and degradation of specific proteins [15].
yclins, cyclin-dependent kinases, and their inhibitors are
arget proteins degraded by the 26S proteasome in an orderly
nd sequential manner to regulate the cell cycle [16]. G1/S
hase progression requires coordination of positive regula-
ors (cyclins, cyclin-dependent kinases [CDKs], CDK-cyclin
omplexes, E2F, and Cdc6) and negative regulators (CDK
nhibitors (CKIs) of the Cip/Kip and INK4 families). Dys-
egulation of these proteins may lead to tumor progression.
roteasomal degradation of p27 (Cip/Kip inhibitor) promotes
ell cycle progression from G0 to G1 [17], consequently ini-
iating the early onset of S phase [18]. For example, high
evels of cyclin E and low levels of p27 (Kip1) expres-
ion have been associated with malignant lymphomas in
umans [19], and the loss of p27 (Kip1) decreases sur-
ival in murine Myc transgenic lymphoma models [20].
n increase in proteasomal degradation of p27 was also
ssociated with decreased overall survival in mantle cell
ymphoma (MCL) in a study of 157 NHL patients with lym-
hoproliferative disorders [21]. A more recent study of 671
iffuse large B cell lymphoma (DLBCL) patients treated
ith rituximab and CHOP (cyclophosphamide, doxoru-
icin/hydroxydaunomycin, vincristine/oncovin, prednisone)
R-CHOP) or without rituximab (CHOP) showed that low
xpression of p27 (Kip1) and increased Skp correlated
ith poor overall and progression-free survival rates [22].
imilarly, p19INK4d is governed by ubiquitination and
ubsequent proteasomal degradation during cell cycle pro-
ression [23]. Genetic defects in the tumor suppressor
NK4a/ARF  locus accelerate lymphomagenesis in an Emu-
yc transgenic murine model, and cytogenetic alterations of
he INK4a/ARF  locus are directly related to drug responses
n primary tumors [24]. The prognostic significance of these
unctional deletions is made evident by the poor progno-
is of subsets of MCL patients with higher levels of cyclin
1, which has been attributed to deletion of the INK4a/ARF
ocus (CDKN2A) [25]. Dysregulated expression or inacti-
ation of p21 promotes cell cycle progression in lymphoma
w
b
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ells in  vitro  and in patients with one of several types of
ymphoma [26–28]. Geminin inhibits DNA replication dur-
ng S, G2, and M phases by preventing the incorporation of
CM proteins into the prereplication complex, thus playing
n important role in DNA replication licensing. Geminin ubi-
uitination by the anaphase-promoting complex/cyclosome
APC/C) ubiquitin-protein ligase and subsequent degradation
y the 26S proteasome permits DNA replication to proceed
29]. Unbalanced expression of geminin is associated with
-cell lymphomagenesis [30] and genomic instability, espe-
ially in MCL with p53/ARF inactivation [31]. In addition,
he overexpression of geminin has been proposed to play a
ole in the pathology of acute leukemia [32].
Cyclins have been directly implicated in the pathogenesis
f lymphoma. Cyclin A is required for entry into mitosis and
-phase progression, and is ubiquitinated and targeted for
roteasomal degradation by APC/C during late M to early
1 phase [33]. Bcl-1 (CCND1 and PRAD1) has been impli-
ated in the pathogenesis of multiple types of NHL, and its
rotein product, cyclin D1, plays an important role in the
ransition from G1 to S phase in response to mitogens. Over-
xpression of cyclin D1 shortens the G1 phase and reduces
he dependency of the cell on extrinsic mitogenic signals.
efects in the proteasomal degradation of cyclin D lead to
ts accumulation within the cell and contributes to prolif-
ration; the prototypical NHL with dysregulation of cyclin
 is MCL [34]. Cyclin E is also required for the onset of
NA replication during late G1 phase and early S phase,
nd is targeted for ubiquitination and subsequent proteaso-
al degradation [35,36]. Cyclin E overexpression has been
bserved in lymphoma [37], particularly DLBCL, and its
verexpression has been associated with poor response to
tandard treatment and inferior outcomes [38]. Of the non-
yclin factors, E2F1 is required for the completion of the
1-to-S-phase transition, and is degraded by the 26S protea-
ome at the S-to-G2-phase transition after dissociating from
he Rb protein [39]. It has been proposed that dysregula-
ion of E2F plays an oncogenic role in sporadic Burkitt’s
ymphoma [40] and in lymphomagenesis in murine models
41]. The Cdc6 protein is a component of the prereplication
omplex required to initiate DNA unwinding and replication
efore S phase [42]. During completion of DNA replication
n S phase, Cdc6 dissociates from DNA-bound replication
omplexes and is ubiquitinated and targeted for proteasomal
egradation by the APC/C [43]. Cdc6 is also overexpressed
n a subset of MCL, in which it is associated with poor clin-
cal outcome [31], and is differentially expressed in primary
utaneous large B-cell lymphoma [44]. In addition, a Cdc6
1321A polymorphism is associated with decreased risk of
HL [45]. These observations suggest that a failure of the
PS to effectively maintain optimal levels of intracellular
yclins can result in hematological malignancies.
Terminal differentiation of eukaryotic cells requires
ithdrawal from the cell cycle, which is accomplished
y the down-regulation of CDK activities during the G1
hase [46]. This mainly occurs in mammalian cells through
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inding of CDKs to the CKIs of the INK4 family (p16Ink4a,
15Ink4b, p18Ink4c, and p19INK4d) and the Cip/Kip family
p21WAF1/Cip1, p27Kip1, and p57Kip2) [47]. More recent stud-
es suggest that proteasomal degradation of p21WAF1/Cip1 and
ther cell cycle regulators, such as cyclin D1 and Cdc25A
hosphatase, can promote differentiation of certain mouse
nd human cells [48,49]. In aggregate, the data indicate
hat the 26S proteasome plays a complex role in cellular
ifferentiation [50].
Heat shock proteins (HSP110, HSP90, HSP70, and
SP27) perform a crucial role as cytosolic molecular chap-
rones in regulating the balance between protein synthesis
nd degradation, stabilizing regulation of signal transduction
athways, and protecting cells from apoptosis in response
o cellular stress [51]. The role of HSP90 in tumorigenesis
as been studied in  vitro  in lymphoma and leukemia models.
SP90 is commonly upregulated in high-grade or large-cell
HL types of B- and T-cell lymphomas [52,53]. Immuno-
istochemical data also show that among B-cell lymphomas,
SP90 is moderately to strongly expressed in Burkitt’s lym-
homa (5/5, 100%) and in subsets of follicular lymphoma
17/28, 61%), DLBCL (27/46, 59%), nodal marginal zone B-
ell lymphoma (6/16, 38%), plasma cell neoplasms (14/39,
6%), small lymphocytic lymphoma/chronic lymphocytic
eukemia (3/9, 33%), MCL (12/38, 32%), and lymphoplas-
acytic lymphoma/Waldenstrom macroglobulinemia (3/10,
0%) [54]. These observations identify a role of HSP90 in
he pathology of lymphomas, and suggest that HSP90 is a
iable therapeutic target of HSP inhibitors in lymphomas.
The proteasomal degradation pathway plays a role in the
nduction and suppression of apoptosis in eukaryotic cells
55]. Among molecules that are regulated by proteasomal
egradation are members of the Bcl-2 family of anti-apoptotic
nd pro-apoptotic proteins. The anti-apoptotic Bcl-2 and
cl-XL proteins are integral mitochondrial proteins that
hare sequence homology in all four Bcl-2 homology (BH1
o BH4) domains but vary in both structure and function.
pon apoptotic stimuli, these proteins block apoptosis and
reserve mitochondrial integrity [34]. Proteasomal degrada-
ion of Bcl-2 results in release of proapoptotic signals and
onsequent promotion of apoptosis [56]. Another class of
nti-apoptotic proteins includes the inhibitor of apoptosis
IAP) family (XIAP and c-IAP2), which inhibits the activa-
ion and enzymatic activity of caspases by targeting them for
biquitination [56,57]. IAPs auto-ubiquitinate via  the RING
nger domain, and subsequent 26S proteasomal degrada-
ion initiates IAP binding to ubiquitin-conjugating enzymes
UbCs, E2) [58]. In these cases, inhibition of proteasomal
egradation of IAP family members enhances proliferative
otential of the treated cells. However, the mechanism under-
ying this effect has not been well demonstrated. Similarly,
ro-apoptotic members of the Bcl family (Bax, Bak, Bad,
im, Bik, and Bid) also undergo proteasomal degradation
59], and inhibition of proteasomal degradation signifi-
antly increases apoptotic potential in treated cells. Thus,
i
c
ygy/Hematology 87 (2013) 306–322 309
locking proteasomal degradation may enhance the activities
f pro-apoptotic proteins rather than those of anti-apoptotic
roteins. Emerging evidence regarding the proteins that con-
titute the apoptotic core machinery and upstream signaling
olecules has revealed multiple new opportunities for ther-
peutic intervention, some of which are already under
nvestigation in clinical trials. With respect to core apopto-
is targets, for example, nuclease-resistant (phosphothioate)
ntisense oligonucleotides directed against BCL-2 mRNA
re currently in phase III trials for patients with multiple
yeloma (MM), and are in phase II trials for patients with
HL, B-cell chronic lymphocytic leukemia (B-CLL), and
cute myeloid leukemia. Small-molecule compounds that
imic the BH3 domains of pro-apoptotic proteins have also
een described [60–62].
The stability and activation of transcription factors are
lso regulated by proteasomal degradation. Dysregulated
xpression of c-Myc is associated with many human can-
ers including Burkitt’s lymphoma, and proteolysis of c-Myc
s mediated by the UPS. Protein levels of c-Myc are over-
xpressed up to 6-fold in Burkitt’s lymphoma-derived cell
ines, and blocking of proteasomal degradation may enhance
-Myc-mediated apoptosis. Aberrant, dysregulated NF-B
ctivation is directly associated with several lymphoid malig-
ancies, and blockage of proteasomal degradation of its
nhibitory IB proteins ablates the survival signals medi-
ted by NF-B and substantially shifts the balance to
ro-apoptotic proteins [63,64].
In addition to the UPS, autophagy machinery is also
mportant for protein degradation in cells via  a lysosome-
ependent degradative pathway [65]. When proteasomes are
nhibited, autophagy is triggered as a compensatory mech-
nism of protein degradation through activation of the ER
tress-induced IRE1 pathway; thus, both systems are func-
ionally coupled in protein degradation. Recent research
nvestigating the role of autophagy in myc-induced lym-
homa derived from p53ERTAM cells demonstrated the
ignificance of autophagy inhibitors (chloroquine) in com-
ination with other therapies for successfully inducing
poptosis in malignant cells [66]. Similarly, in leukemia,
eregulation of autophagy points to the fact that autophagy
nhibitors could be included in combination therapies for
uppressing cancer progression [65].
. Current  therapeutic  options  for  lymphoma
To treat NHL, the combination chemotherapy regi-
en CHOP is most commonly used [67]. Other treatment
ombinations for NHL include common chemotherapy
gents such as chlorambucil, methotrexate, vinblastine,
toposide, cytarabine, fludarabine, and cladribine, and
adioimmunotherapeutic agents including tositumomab and
britumomab. For Hodgkin’s lymphoma (HL), which can be
ured in about 75% of cases overall and 90% of cases in
ounger patients [68], a combination chemotherapy regimen
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f ABVD (adriamycin, bleomycin, vinblastine, dacarbazine)
s most commonly used. Radiation therapy may be used alone
or treating HL, or may be combined with chemotherapy and
ith stem cell transplantation after failure of primary therapy
69]. For MCL, which is clinically aggressive with poor prog-
osis, rituximab and ASCT (Allogeneic/Autologous Stem
ell Transplant) prolongs progression-free survival. How-
ver, for patients who are not fit for intensive treatment,
ess intensive treatment with various combinations of ritux-
mab and other compounds, such as rituximab with CHOP or
ith bendamustine is recommended, and for relapsed MCL,
SCT can be effective if a compatible donor is available
reviewed in Cortelazzo et al. [70]). In addition to con-
entional combination chemotherapy, proteasome inhibitors
ave been used to treat lymphomas. This class of compounds
onsists of synthetic and natural products and can be catego-
ized into five different classes (A to E) based on chemical
tructure.
.1.  Class  A  compounds
Class A compounds are peptide aldehydes and include
G 132 and MG 115. These compounds primarily inhibit
hymotrypsin-like activity through the formation of a cova-
ent bond between the aldehyde and an N-terminal threonine
oiety in a reversible manner. The specificity of class A
ompounds is relatively low. Well-known peptide aldehyde
nhibitors have been further refined for specificity by using
eptide vinyl sulfones and peptide-boronic acid derivatives.
hese efforts have led to the development of highly potent
nd specific drugs like PS-341 (bortezomib) [71] and CEP-
8770, which is currently being clinically evaluated (Table 1)
Fig. 2).
.2.  Class  B  compounds
Class B compounds are synthetic peptide boronates,
nd including benzamide, alpha-ketoamide, bortezomib, and
bz-Leu-Leu-Leu-boronic acid. Bortezomib  binds with high
ffinity and specificity (yet reversibly) to the threonine
ydroxyl groups in the chymotrypsin-like active site of the
roteasome 5 subunit and inhibits the peptidyl-glutamyl
eptide-hydrolyzing activity of the 1 subunit. Bortezomib
as shown promising activity and has led to durable responses
s a single agent in relapsed or refractory MCL patients and
M patients [72,73]. In a phase II trial (n  = 202), the over-
ll response rate (ORR) and complete response rate (CR)
f patients with MM treated with bortezomib were 35%
nd 4%, respectively, with a median overall survival of 16
onths [74]. Similarly, heavily pre-treated MCL patients
n = 36) responded to bortezomib favorably with an ORR of
6.5% and a CR of 16% [75]. While somewhat less success-
ul, encouraging responses have also been seen in patients
ith DLBCL, follicular lymphoma (FL) [76], Waldenstrom
acroglobulinemia [77], and in patients with a few solid
umors including sarcoma [78], renal cell carcinoma [79], and
w
[
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on-small cell lung carcinoma [80]. More recently, accumu-
ating evidence has shown that the efficacy of bortezomib
an be enhanced through combination with chemother-
py. When combined with doxorubicin-based chemotherapy,
ortezomib resulted in an 83% higher response rate in
elapsed/refractory activated B-cell-like DLBCL, and in a
3% higher response rate in relapsed/refractory germinal cen-
er B-cell-like DLBCL [81]. In addition, a combination of
ortezomib with irinotecan in a phase II clinical trial pro-
uced improvements in the ORR from 9% (bortezomib alone)
o 44% (bortezomib/irinotecan) in advanced gastric cancer
n = 28) [82]. More recently, in a phase II trial of 63 refractory
nd relapsing FL patients, bortezomib combined with ben-
amustine and rituximab resulted in an 88% ORR (including
 53% CR), with toxicity within manageable limits [83]. In
 separate phase II clinical trial of 94 untreated advanced
tage (III/IV) FL patients, bortezomib added to rituximab,
yclophosphamide, vincristine, and prednisone resulted in
n intent-to-treat outcome of 46 of 94 patients (49%; 95%
onfidence interval [CI] of 38.8–59.0%) who achieved a
R or unconfirmed CR, and 32 of 94 patients (34%) who
chieved a partial response, for an overall response rate of
3% (95% CI of 75.4–90.6%) [84]. In this study (Table 1),
o grade 4 neurotoxicity was observed, although 5 patients
eveloped largely reversible grade 3 neurotoxicity. Other
ombinations that have shown encouraging results in hemato-
ogical malignancies include thalidomide and its derivatives,
avopiridol (cyclin inhibitor), rapamycin (mTOR inhibitor),
nd dexamethasone, doxorubicin, melphalan, and prednisone
85,86]. In fact, a multicenter phase II trial of 29 evaluable
elapsed/refractory indolent and mantle cell NHL patients
reated with 90 mg/m2 of bendamustine on days 1 and 4;
75 mg/m2 rituximab on day 1, and 1.3 mg/m2 bortezomib
n days 1, 4, 8, and 11, on six 28-day cycles resulted in
 47% 2-year progression-free survival rate (15/29 patients
chieved complete response) [87]. In another phase II clin-
cal trial of 16 relapsed and chemotherapy-refractory MCL
atients treated with bortezomib combined with rituximab
nd dexamethasone (treatment cycle consisted of bortezomib
1.3 mg/m2 on days 1, 4, 8, and 11; six 21-day cycles], rit-
ximab [375 mg/m2 on day 1], and dexamethasone [40 mg
rally on days 1–4]) resulted in 13 patients (81.3%) achiev-
ng responses and 7 patients achieving complete responses
43.8%) [88]. In addition, in chemotherapy-naïve low-grade
HL, bortezomib combined with rituximab, dexamethasone,
nd cyclophosphamide (bortezomib given at 1.6 mg/m2, on
ays 1, 8, 15, and 22 of every 35-day cycle; rituximab given
t 375 mg/m2 on the same days as bortezomib during cycle
 and then only on day 1 in subsequent cycles; dexametha-
one given orally at 40 mg on days 1, 2, 8, 9, 15, 16, 22, and
3; and cyclophosphamide administered orally at 400 mg/m2
n days 1–4) resulted in an ORR of 90% (CR of 54%),
ith a 75% (n  = 9) survival rate at a 22-month follow-up
89]. In this study, there were no grade 3 or 4 periph-
ral neuropathies. In addition, results from in  vitro  studies
ith cells derived from primary effusion lymphomas showed
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Table 1
Clinical trials of the major proteasome inhibitors in lymphoma therapy.
Proteasome Inhibitors in treatment for lymphoma
PI Condition Dose Toxicity n (patients) Phase CR PR TTP ORR NCT Status
Bortezomib MCL 1.3 mg/m2 given on days 1,
4, 8 and 11 every 21 days
Neurological toxicity,
dyspnea, myalgia/edema
30 Phase 2 NA NA 10 months 46% NCT00030875 Completed
Bortezomib MCL 1.3 mg/m2 i.v. on days 1, 4,
8, and 11 of each 3-week
cycle
Asthenia, peripheral
neuropathy, constipation,
nausea, anorexia
155 Phase 1 8% NA 15 months 31% [154] Completed
Bortezomib Indolent-NHL and
MCL
1.5 mg/m2 on days 1, 4, 8,
and 11
Lymphopenia,
thrombocytopenia
26 Phase 2 7% 37% 11–24+ months 58% NA Completed
Bortezomib RR B-cell NHL
[A] Bortezomib was
administered IV
(1.5 mg/m2) on days 1, 4, 8,
and 11 every 21 days for a
maximum of 6 cycles
Thrombocytopenia,
fatigue, neutropenia,
peripheral neuropathy
33/60 Phase 2 18% 18% 24 months 41% NCT00038571 Completed
[B] Bortezomib was
administered IV
(1.5 mg/m2) on days 1, 4, 8,
and 11 every 21 days for a
maximum of 6 cycles
Thrombocytopenia,
fatigue, neutropenia,
peripheral neuropathy
27/60 Phase2 15% 5% 24 months 19% NCT00038571 Completed
Bortezomib
+ Bendamustine
+ Rituximab
R/R-FL Bortezomib 1.6 mg/m2 IV
on days 1, 8, 15, and 22 of
each 35-day cycle;
bendamustine 50–90 mg/m2
IV on days 1 and 2 of each
cycle; rituximab 375 mg/m2
IV on days 1, 8, 15 and 22
of cycle 1 and on day1 of
cycles 2, 3, 4, and 5. Total
treatment duration is 5
cycles.
Pancytopenia,
thrombocytopenia,
neutropenia
73 Phase 2 53% 35% NA 88% NCT00636792 Completed
Bortezomib + CHOP T-cellor NK/T cell
Lymphomas
NA NA 55 Phase 1–2 NA NA NA NA NCT00374699 Completed
Bortezomib + R-
CHOP
MCL, DLBCL R-CHOP was administered
on a 21-day cycle for 6
cycles, with 1 of 3 dose
levels of bortezomib
administered on Days 1 and
4 of each cycle.
Neuropathy, hematologic
toxicity
20 Phase 1 95% 5% 4 years 75% [155] Completed
Bortezomib + R-CP R/R indolent NHL Cyclophosphamide IV and
rituximab IV on day 1, oral
prednisone on days 2–6,
and bortezomib IV (at the
MTD determined in phase
I) on days 2 and 8.
Treatment repeats every 21
days for up to 8 courses
NA 115 Phase 2 NA NA NA NA NCT00295932 Recruiting
312
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Table 1 (Continued)
Proteasome Inhibitors in treatment for lymphoma
PI Condition Dose Toxicity n (patients) Phase CR PR TTP ORR NCT Status
Bortezomib + PD0332991Relapsed MCL PD 0332991 will be
administered continuously
for 12 days followed by a 9
day period without
treatment. Bortezomib will
be administered by
intravenous bolus on days 8,
11, 15, and 18 of each cycle
NA 30 Phase 1 NA NA NA NA NCT01111188 Recruiting
Carfilzomib MCL/MM Every 14 days at 1.2, 2.4,
4.6, 4.4, 11, 15 and
20 mg/m2, with no dose
limiting toxicities up to
15 mg/m2 cohorts while at
20 mg/m2
Diarrhea, fatigue and
nausea
29 Phase 1 3.5% 3.5% NA NA [109] Completed
Carfilzomib + Vorinostat R/R-Lymphoma Carfilzomib 30 min infusion
daily for days 1, 2, 8, 9, 15,
16, Every 28 days,
maximum 13 cycles.
Vorinostat by mouth 2×
daily on days 1, 2, 3, 8, 9,
10, 15, 16 and 17.
Maximum 13 cycles.
NA 24 Phase 1 NA NA NA NA NCT01276717 Recruiting
NPI-0052 Lymphoma 0.7 mg/m2 on days 1, 8, and
15 every 28 days
Fatigue, mental status
change, loss of balance
30 Phase 1 None 3.5% NA 3.5% [156] Completed
NPI-0052 R/Lymphoma IV 3×, every 28 days NA 50 Phase 1 NA NA NA NA NCT00396864 Recruiting
NPI
0052 + Vorinostat
Lymphoma NPI-0052 IV weekly
vorinostat oral daily
NA 40 Phase 1 NA NA NA NA NCT00667082 Recruiting
CEP 18770 NHL Days 1, 4, 8, and 11 of a
21-day cycle up to 6 cycles.
Starting dose 0.1 mg/m2
NA 55 Phase 1 NA NA NA NA NCT00572637 Completed
MLN9708 Lymphoma Days 1, 8, and 15 of a
28-day cycle, Starting dose
0.125 mg/m2
NA 34 Phase 1 NA NA NA NA NCT00893464 Recruiting
Abbreviations: CR, complete response; PR, partial response; TTP, time to progression; ORR, overall response rate; NCT, number of clinical trial (http://clinicaltrials.gov/).
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vig. 2. Chemical structures of major proteasome inhibitors in the treatment
hat treatment with bortezomib in combination with doxoru-
icin and Taxol was schedule-dependent, and was additive
ith tumor necrosis factor-related apoptosis-inducing ligand
TRAIL) and synergistic with dexamethasone [90]. A recent
eport demonstrated that cytarabine interferes with DNA
olymerases and incorporates into the genome during DNA
eplication, consequently arresting cell cycle progression
91]. Furthermore, cytarabine shows sequence-dependent
ynergism with bortezomib in MCL [92]. A combination
f rituximab and bortezomib for treatment of MCL, FL,
nd marginal zone lymphoma is under clinical development
93].
The safety of bortezomib has been demonstrated by clini-
al trials (Table 4). One such study was a phase II, multicenter
linical trial of patients with relapsed or refractory MCL
PINNACLE study). In total, 152 patients were treated with
ortezomib administered at 1.3 mg/m2 intravenously (IV) on
ays 1, 4, 8, and 11 of a 21-day cycle for up to 17 cycles
94]. The most common non-hematologic adverse effects of
rade 3 or higher were diarrhea (11 patients, 7%), fatigue (19
atients, 12%), and peripheral neuropathy (20 patients, 13%).
he median onset of neuropathy was estimated at 12 weeks.
owever, data on reversibility was not collected. The most
ommon hematologic toxicity was thrombocytopenia, which
ccurred in 17 (11%) patients. Five (3%) patients died from
ortezomib-associated causes, including non-neutropenic
epsis and respiratory failure. The most common adverse
ffects leading to treatment discontinuation were peripheral
europathy (10%) and fatigue (6%). The safety of bortezomib
as evaluated in another phase II clinical trial in patients
ith relapsed or refractory cutaneous T-cell lymphoma95]. Patients were treated with bortezomib administered at
.3 mg/m2 IV on days 1, 4, 8, and 11 of a 21-day cycle for up
o six cycles. Fifteen patients were registered and 12 were
s
e
ahoma bortezomib, CEP 18770, marizomib, ixizomib and carfilzomib.
ssessed. Bortezomib was well tolerated with no grade 4
oxicity. The most common grade 3 hematologic toxicities
ere neutropenia (2 patients, 17%) and thrombocytopenia
2 patients, 17%). However, no grade 3 or higher anemia
as recorded. The most common non-hematologic toxic-
ty was sensory neuropathy, which was observed in 50% of
atients. One patient (8%) reported grade 3 sensory neuropa-
hy but had complete recovery within six weeks. There was no
bservation of GI toxicity or fatigue, perhaps due to inherent
ifferences between diseases or differences in prior therapy.
The safety profile of bortezomib for use in lymphoma
reatment appears to be similar to previous experiences in
M. During the first phase II clinical trial, the Study of
ncontrolled Multiple Myeloma Managed with Proteasome
nhibition Therapy (SUMMIT), bortezomib was adminis-
ered at 1.3 mg/m2 IV on days 1, 4, 8, and 11 of a 21-day
ycle for a maximum of eight cycles [96]. Grade 3 toxicities
ncluded thrombocytopenia (28%), peripheral neuropathy
12%), fatigue (12%), and neutropenia (11%). A second
hase II trial, the Clinical Response and Efficacy Study of
ortezomib in the Treatment of Relapsing Multiple Myeloma
CREST) (Table 2), was an open-label, randomized trial
f 54 patients who were previously treated for MM [97].
atients were randomized to receive bortezomib at a dose of
.3 mg/m2 or 1 mg/m2 IV using the same dosing schedule as
he SUMMIT trial (Table 2). The incidence of drug-related
dverse effects was considerably lower for patients receiv-
ng 1 mg/m2 versus  1.3 mg/m2. The most common adverse
ffects were peripheral neuropathy (58% vs.  19%), diarrhea
65% vs.  25%), nausea (62% vs.  46%), and vomiting (38%
s. 14%). The relatively common occurrence of peripheral
ensory neuropathy associated with bortezomib necessitates
arly detection, and recommendations for dose modifications
re detailed in Table 3 [98].
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Table 2
Combined safety data for pivotal phase II clinical trial results for patients with multiple myeloma at standard doses.
Study Dose Patients Toxicity ≥ 20% Overall (%)/Grade 3 (%)
SUMMIT trial [96]
1.3 mg/m2 202 Nausea and vomiting 55%/6% and 27%/8%
Diarrhea 44%/7%
Fatigue 41%/12%
Thrombocytopenia 40%/28%
Peripheral neuropathy 31%/12%
Anemia 21%/8%
CREST trial [97]
1.3 mg/m2 28 Nausea 41%/0%
1 mg/m2 26 Diarrhea 39%/4%
Fatigue 56%/7%
Thrombocytopenia 28%/22%
Peripheral neuropathy 35%/9%
Table 3
Prescribing information: recommended dose modifications for bortezomib-related neuropathic pain and/or peripheral sensory or motor neuropathy [97].
Severity of peripheral neuropathy Modification of dose and regimen
Grade 1 (asymptomatic; deep tendon reflex loss or
paresthesia) without pain or loss of function
No action needed
Grade 1 with pain or Grade 2 (moderate symptoms; limiting
instrumental activities of daily living)
Reduce bortezomib dose to 1 mg/m2
Grade 2 with pain or Grade 3 (severe symptoms; self-care
limiting activities of daily living)
Withhold bortezomib therapy until symptoms of toxicity resolve; after symptoms resolve,
reinitiate bortezomib at 0.7 mg/m2 and change treatment schedule to once weekly
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Grade 4 (life-threatening consequences with urgent
intervention indicated; permanent sensory loss)
Discontinu
A number of conclusions and recommendations can be
rawn from these trials. Both of these myeloma trials con-
rm that thrombocytopenia is not associated with serious
leeding events (Table 2), although one patient developed
n episode of gastrointestinal bleeding with grade 3 throm-
ocytopenia (platelet count < 50,000 mL−1). Anemia and
eutropenia associated with bortezomib are usually not prob-
ematic. Fatigue usually occurs during cycles 1–2 and may
ersist for several cycles before subsiding. Treatment should
e withheld at the onset of any treatment-associated grade
 fatigue. Once symptoms resolve, bortezomib therapy may
e reinitiated with a 25% dose reduction. Bortezomib does
ot appear to be directly cytotoxic to most normal bone
arrow cells or to destroy progenitor cells [99]. Complete
lood counts should be performed prior to bortezomib dose
dministration. Dose adjustments for bortezomib-associated
ematologic toxicity are detailed in Table 4. Gastrointestinal
dverse events occur frequently, with the most common being
ausea, diarrhea, constipation, and vomiting. These gastroin-
estinal disturbances can occur at any time during treatment,
ut in clinical trials they have occurred most frequently
c
o
w
(
able 4
rescribing information: recommended dose modifications for bortezomib-related h
ematologic toxicity Modification of do
latelets ≤30,000 mm−3 or absolute neutrophil count
≤750 mm−3 on bortezomib treatment day(s) (except day 1)
Withhold bortezom
dose 1 level (1.3 m
0.7 mg/m2/dose)
rade 4 hematological toxicity: platelets ≤25,000 mm−3 or
absolute neutrophil count ≤500 mm−3 on bortezomib
treatment day(s)
Withhold until tox
reduced to 1 mg/mzomib treatment
uring cycles 1–2. Nausea and vomiting may require the use
f anti-emetics; diarrhea may be controlled with antidiar-
heal medications, and constipation can be managed with
tool softeners and laxatives (Table 4).
There have been a number of attempts to identify biomark-
rs to predict responses to bortezomib to spare a population
f patients that is unlikely to respond favorably to the drug.
 few studies showed that antitumor activity of bortezomib
s greater against tumors with an NF-B mutation and cyclin
 overexpression (JNCI). Such pre-selection may potentially
mprove ORR while sparing unnecessary exposure to therapy.
.3.  Class  C  compounds
Class C compounds are the first natural proteaso-
al inhibitors discovered and contain -lactone structures.
ore recent experiments have demonstrated that lacta-ystin blocks cell-cycle progression, inhibits degradation
f KIP1, and induces apoptosis of activated B-CLL cells
ith little effect on resting B-CLL cells [3]. NPI-0052
marizomib; Fig. 2) was originally isolated from marine
ematologic toxicities [97].
se
ib; if several bortezomib doses in consecutive cycles are withheld, reduce
g/m2/dose reduced to 1 mg/m2/dose; 1 mg/m2/dose reduced to
icity resolved; may reinitiate with a 25% dose reduction (1.3 mg/m2/dose
2/dose; 1 mg/m2/dose reduced to 0.7 mg/m2/dose)
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acteria. It resembles lactacystin, and is used largely for
ancer treatment. However, unlike bortezomib, NPI-0052
rreversibly inhibits the three major enzymatic activities
chymotrypsin-, trypsin-, and caspase-like) of the 20S pro-
easome [71,100]. When compared to bortezomib, NPI-0052
xhibits an improved therapeutic ratio and significant activity
n hematologic malignancies and solid tumors, includ-
ng bortezomib-resistant MM. To overcome inherent and
cquired bortezomib resistance and for broader anti-cancer
ffects, NPI-0052, with its structural and pharmacological
niqueness, is being tested both as a single agent and as com-
ined with biologics and targeted therapeutic agents (Table 4)
101]. This marine-derived, orally active, broad-spectrum
roteasome inhibitor has shown potent antitumor activity in
eukemia in  vitro  and in a leukemic mouse model in  vivo
102,103]. Interestingly, combining NPI-0052 with either
S-275 or valproic acid (VPA) induced greater levels of cell
eath than the combination of bortezomib with these histone
eacetylase (HDAC) inhibitors [102]. A phase II clinical trial
n = 30) demonstrated that NPI-0052 was well tolerated and
nhibited caspase- and trypsin-like activities with 51% and
2% efficacy, respectively, which led to stable disease in 31%
f cases in MCL, HL, FL, and other solid tumors [104]. Simi-
ar to bortezomib, NPI-0052 increased cytotoxic effects when
sed in combination with 5-fluorouracil, CTP-11, Avastin
bevacizumab), leucovorin, or oxaliplatin in tumor xenograft
odels (Fig. 2) [105]. Due to the greater potency of NPI-0052
ompared to bortezomib in increasing apoptotic potential in
LL and in preclinical settings [106], further clinical devel-
pments are expected.
.4.  Class  D  compounds
Class D proteasomal inhibitors have epoxyketone struc-
ures. The efficacy of the class D compound carfilzomib is
nder investigation in clinical trials (Table 1). Carfilzomib
Fig. 2) is an irreversible proteasomal inhibitor that primarily
nhibits chymotrypsin-, trypsin-, and caspase-like activities
f the proteasome. It has equal potency but greater selectiv-
ty for the chymotrypsin-like activity of the proteasome than
ortezomib, causing stronger cytotoxic effects and enhanc-
ng cell cycle arrest and apoptosis in  vitro. In animal studies,
arfilzomib-mediated inhibition of proteasome activity was
ound to occur in a dose-dependent manner in all tissues
xamined, with the exception of the brain [71]. Epoxomicin
s a selective, irreversible inhibitor of the chymotrypsin-like
ctivity of the proteasome, which promotes proapoptotic
ctivity in anaplastic large-cell lymphoma cell lines [107]
nd in Bcl-2-overexpressing recombinant Jurkat cells in  vitro
108]. Carfilzomib is being evaluated in early clinical trials
nd in a phase I trial in patients with refractory and relapsed
ematologic malignancies, including MM and MCL. In the
atter trial (n  = 29), carfilzomib was administered every day
or 5 consecutive days every 14 days at 1.2, 2.4, 4.6, 4.4,
1, 15, and 20 mg/m2. No dose-limiting toxicities were
bserved up to 15 mg/m2. At 20 mg/m2, two of five patients
w
f
o
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xhibited grade 3 thrombocytopenia, thus establishing
5 mg/m2 as the maximum tolerated dose (Table 3). Anti-
umor responses were observed at doses ≥11 mg/m2. More
han one-third of patients experienced grade 1 or 2 non-
ematologic toxicities including diarrhea, fatigue, and nausea
n the absence of grade 3–4 peripheral neuropathy, whereas
8% (n  = 14) of patients experienced grade 3–4 toxicity, thus
stablishing the reduced incidence of neuropathy associ-
ted with carfilzomib [109]. Co-administration of carfilzomib
subtoxic or minimally toxic levels) in combination with
he histone deacetylase inhibitor vorinostat potentiates the
ctivities of carfilzomib including mitochondrial injury, cell
ycle arrest, and caspase activation, leading to apoptosis in
oth germinal-center B cell-like DLBCL and activated B
ell-like DLBCL [110]. Given the promising results of com-
inatorial drug administration with proteasome inhibitors and
istone deacetylase inhibitors, a phase I clinical trial has been
stablished for carfilzomib (PR-171) in combination with
orinostat (SAHA) in patients with relapsed/refractory B cell
ymphomas [111] (Table 1).
.5.  Class  E  compounds
Class E compounds are macrocyclic vinyl ketones
hat irreversibly inhibit proteasomal activity. While small-
olecule inhibitors in general suffer from poor pharma-
okinetics due to rapid renal clearance, more potent and
ustained effects can be expected from these newly developed
rreversible proteasomal inhibitors.
As a part of developing combination therapy for hemato-
ogical malignancies, the BH3- mimetic ABT-737 was found
o exhibit synergistic potential in combination with borte-
omib against CLL, MCL, and DLBCL. Among these, MCL
howed the highest sensitivity toward ABT-737 and DLBCL
howed the least [112]. Currently ABT-737 is in a clinical trial
n oral form as ABT-263, which exhibits high-affinity binding
o Bcl-2 and Bcl-xL, thus inducing apoptosis by preventing
he sequestration of proapoptotic molecules in hematological
alignancies, including MM [113,114]. Similarly, the anti-
umor effects and sensitivity of tumor cells to ABT-737 have
een assessed in six MCL cell lines and in primary MCL cells
n = 13); the results showed that ABT-737 induces apoptosis
n MCL cells that express a Bcl-2high/Mcl-1low profile [115].
his study shows that down-regulation of Mcl-1 enhances
he effects of ABT-737, and indicates that the Bcl-2/Mcl-1
rofile of the tumor should guide the use of ABT-737 in the
reatment of MCL.
In addition to the use of drugs that inhibit proteasomal
ctivity, other enzymes such as E3 ligase or de-ubiquitylating
nzymes may be additional, alternative molecular targets
or effectively inhibiting the proteasomal degradation path-
ay [116]. The ubiquitin-like molecules represent another
amily of enzymes of interest for drug development. Numer-
us substrates for SUMO and NEDD8 have been identified
s drugable targets by proteomics approaches [71]. Major
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roteasomal inhibitors currently being evaluated in clinical
rials are listed in Table 1.
Similarly, HDAC inhibitors have been reported to have a
ynergistic effect in MCL therapy when combined with pro-
easomal inhibitors, where the combination induces higher
ytotoxicity and cell death. Studies on interactions of SAHA
HDAC inhibitor) with bortezomib in MCL reveal that the
ombination of both drugs synergistically induces apoptosis
n MCL cells [117].
.  Unfolded  protein  response  (UPR)
Cellular stress can cause disruption in peptide processing
n endoplasmic reticulum either by altering Calcium levels
r by interfering with glycosylation and disulfide bond for-
ation, leading to the induction of a cascade of intracellular
tress signaling—the UPR (unfolded protein response)—due
o the accumulation of the unfolded proteins. Induction of
he UPR results in a reduction in general protein synthesis,
n increase in clearing misfolded proteins, and a restoration
f peptide processing in the ER lumen. IRE-1 and ATF6
an induce UPR since they are ER proximal stress sensing
olecules [118,119]. In stressed normal cells, UPR ame-
iorates protein misfolding and helps the cells to survive
he stress. However, in tumorigenesis, UPR plays a signif-
cant role in maintaining malignancy and chemoresistance
f malignant cells by upregulating the expression of XBP1,
nducing ATF4 and CHOP (C/EBP homologous protein), and
ctivating ATF6 [120].
Recent studies have revealed that proteasomal inhibitors
e.g., bortezomib) induce endoplasmic reticular stress and
PR in MM cells. The intensity of the response to borte-
omib depends on levels of XBP1 [121]. Also, proteasomal
nhibitors cause accumulation of unfolded proteins in tumor
ells, and trigger proapoptotic signaling leading to cell death
120]. In MM cells, bortezomib and tunicamycin activate
R stress specific PERK (PKR-like ER kinase) in less than
n hour. Similarly, constitutive expression of physiologic
PR genes is necessary in MM cells since they produce
ignificant amounts of immunoglobulin which causes them
o be inherently sensitive to proteasome inhibitors, espe-
ially bortezomib, which selectively induces apoptosis in
M cells. However; MM cells constantly express ER stress
urvival proteins necessary to support their role as secre-
ory cells; hence, they have a lower threshold for proteasome
nhibitor-induced UPR induction and ER stress-induced apo-
tosis [122]. Moreover, as detailed analysis of the role of
PR in balancing apoptosis of cancer cells, dormancy, and
nvasive growth and increasing susceptibility of tumors to
hemotherapeutic agents has shown (reviewed earlier by Ma
nd Hendershot [123]), prolonged activation of UPR could
esult in apoptosis.
Similarly, inhibition of UPR plays a significant role
n reducing the resistance of MCL cells to proteasome
nhibitors, thereby increasing the efficacy of treatment. In
3
u
d
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 recent study analyzing 18 MCL samples including cell
ines, Roué et al. demonstrated that loss of sensitivity of
CL cells to proteasome inhibitors is related to the up
egulation of prosurvival chaperone BiP/Grp78 and to the
tabilization of this protein by increased chaperoning activ-
ty of Hsp90 (Heat shock protein 90 kDa). Knocking down
f BiP/Grp78 coupled with Hsp90 inhibitor IPI-504 (class:
nsamycin) in combination with bortezomib resulted in apo-
tosis of MCL cells. Results of this study further indicate that
n MCL cultures and tumors the combination of bortezomib
nd IPI-504 can overcome both intrinsic and acquired resis-
ance via  dissociation of Hsp90/BiP complexes, BiP/Grp78
epletion, inhibition of UPR, and thus, enhanced cell death,
uggesting the effectiveness of this combination in treat-
ent of patients with MCL refractory to bortezomib therapy
124].
.  Apoptosis
Proteasome inhibitors mediate cell cycle arrest and apo-
tosis by causing dysregulation of a number of proapoptotic
roteins in lymphoma cells [125]. Earlier studies reported
he accumulation of p53 in cells treated with proteasome
nhibitors, causing up regulation of the p53-inducible gene
roducts p21 and Mdm-2[126]. In normal cells, the RING
omain of Mdm2 or Hdm2 (the human counterpart of Mdm2)
inds to the tumor suppressor p53, and an E3 ubiquitin ligase
hen targets p53 to enhance its rapid degradation [127]. Upon
roteasome inhibitor treatment, p53-Mdm2 binding is inter-
upted; p53 becomes phosphorylated, and initiates proapop-
otic signaling [128]. Disruption of the p53–Mdm2 interac-
ion leads to defective apoptosis [129], and overexpression of
ild type p53 increases sensitivity to proteasome inhibitors
n Burkitt’s lymphoma, suggesting that effective apoptosis
ediated by proteasome inhibitors requires an intact p53
athway [130]. In contrast, recent reports indicate that borte-
omib induces apoptosis by mitotic catastrophe independent
f p53 activity in B-cell lymphoma cells in  vitro  [72].
Proteasome inhibitors activate apoptosis in Lymphoma
ells. Two major pathways are involved in apoptosis-
ssociated caspase activation in mammalian cells: the
xtrinsic death receptor pathway, which is regulated by mem-
ers of the death receptor superfamily, and the intrinsic
itochondrial pathway, which is associated with extracel-
ular cues and internal insults [131]. The active form of
aspase-3 is necessary to cleave the other initiator caspases,
hich ultimately leads to the cleavage of many cellular pro-
ein substrates and apoptosis. It has recently been shown that
aspase-3 is degraded by the 26S  proteasome. Proteasome
nhibitors induce the accumulation of caspase-3 subunits and
nhance apoptosis induced by overexpression of pro-caspase- [132]. Another indication that caspase-3 is targeted by
biquitination for degradation is that monoubiquitination or
iubiquitination of caspase-3 subunits was seen after protea-
ome inhibitor treatment of cells [133,134].
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TRAIL has the ability to induce apoptosis in cancer cells
ith little or no toxicity to normal cells. Death receptor 5
DR5; also called TRAIL-R2, Apo2, TRICK2, or KILLER)
s a receptor for TRAIL. In fact, preclinical studies in mice
rovided the first evidence that the soluble form of recom-
inant TRAIL would suppress the growth of human tumor
enografts with no apparent systemic toxicity [135]. DR5
ediates TRAIL-induced apoptosis through the interaction
ith adapter proteins, such as FADD, and through caspase
ctivation [136]. Ubiquitin ligases bind to caspases, resulting
n the degradation of these caspases and possibly tumori-
enesis. However, proteasome inhibitors can induce DR5
xpression and sensitize tumor cells to TRAIL-induced apo-
tosis [137–139].
Proteasome inhibitors also induce the activation of Bax, a
ember of the proapoptotic Bcl-2 family, which is required
or apoptosis [140]. As a result of apoptotic signaling and
aspase activation, the BH3 domain of Bax dimerizes and
ecomes resistant to proteasomal degradation. Bax then
ranslocates into the mitochondria, which leads to the release
f proapoptotic mitochondrial factors such as cytochrome c
esulting in apoptosis [139].
Proteins known as -transducin repeat-containing pro-
eins (-TrCPs) play a role as substrates of E3 ubiquitin
igases that control stability of important regulators of the cell
ycle and signal transduction [141]. One of the major mech-
nisms of the anticancer effects of proteasomal inhibitors is
hought to be the suppression of prosurvival NF-B due to sta-
ilization of its inhibitor IB [142]. Proteasomal degradation
f IB requires phosphorylation-dependent ubiquitination,
hich is mediated by -TrCPs [143,144]. Thus, -TrCP func-
ion is essential for the induction of NF-B transcriptional
ctivities, which play a key role in proliferation and survival
f cancer cells and are often augmented in human cancers
141].
NF-B activation contributes to many aspects of tumor
evelopment, such as accelerated cell cycle progression, cell
roliferation, tumor initiation, and metastasis. As a major
ntiapoptotic factor, NF-B is involved significantly in the
esistance of tumors to chemotherapy and radiation. Constitu-
ive activation of NF-B is seen in many human malignancies,
ncluding breast cancer [145]. Furthermore, -TrCP1 and
-TrCP2 proteins seem to play a redundant role in ubiquitin-
tion and degradation of IB. Also, expression of -TrCP2 is
nduced in human breast cancer cell lines and primary tumor
amples [143,146].
Targeting -TrCP for inhibition with an RNAi approach
r forced expression of a dominant-negative -TrCP mutant
uppresses growth and survival of human breast cancer cells.
n addition, inhibiting -TrCP augments the antiproliferative
ffects of anticancer drugs such as doxorubicin, tamoxifen,
nd paclitaxel on human mammary tumor cells. These data
ndicate that targeting -TrCP is a likely beneficial approach
or anticancer therapies [141].
Bortezomib is capable of inhibiting the 26S protea-
ome, and has the ability to target a number of different
F
h
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athways in the cell including (1) the inhibition of NF-B,
hich contributes to many features of the malignant phe-
otype, (2) maintenance of p27 and p21 levels, which are
ell cycle-dependent kinase inhibitors, (3) accumulation of
roapoptotic proteins in the mitochondria, and (4) effects on
ytokines and cell adhesion molecules [147]. The UPS tar-
ets the p27 protein in MCL, whereas, in FL and aggressive
ymphoma, NF-B is targeted.
Proteins like p21 and p27 are members of the Cip/Kip
amily of cyclin-dependent kinase inhibitors that promote
ell cycle progression at the G1-S phase junction by inac-
ivating cyclin/cdk complexes [147,148]. These proteins are
ubstrates for the UPS, and drugs that affect this pathway
ould lead to the accumulation of regulatory proteins that
ould cause cell cycle arrest. Most cases of MCL (91/112)
nd DLBCL (12/19) have been shown to have lost expres-
ion of p27 [21,149], but other subtypes of NHL such as
mall lymphocytic lymphoma and extranodal marginal zone
ymphomas have not been found to have any loss of p27
xpression [149].
Molecular and in  vivo  protein degradation assays showed
hat MCL exhibited normal p27 mRNA expression but
ncreased p27 protein loss. Correlation of the p53 and p27
efects with clinical data from patients with MCL indicates
hat patients with both defects exhibit a significant reduc-
ion in overall survival. The explanations for the loss of p27
ight be (1) the possible sequestration of p27 by cyclins
1 and D3, which are overexpressed in MCL and (2) an
ver-accumulation of Skp2, which is a part of the p27Kip1
biquitin ligase (E3) combination that plays a significant role
n the degradation of the CDK inhibitor [147,149]. High
evels of Skp2 correlate with greater E3 enzyme activity,
hich ultimately leads to proteasome-mediated degradation
f the target protein p27. In large B-cell lymphomas and
lastic MCL, elevated Skp2 levels were significantly asso-
iated with a low p27Kip1 level, indicating that increased
roteasome-mediated degradation of p27Kip1 contributes
o the malignant phenotype [149], an observation in MCL
hat provides a powerful rationale for the use of proteasome
nhibitors in lymphoma [147].
FL is characterized by the translocation of the Bcl-2 proto-
ncogene from chromosome 18q21 to the immunoglobulin
eavy chain locus at chromosome 14q32 [150]. This
ranslocation t(14:18) leads to the overexpression of the anti-
poptotic Bcl-2 protein, which is driven by NF-B, protecting
ells from apoptosis. Furthermore, NF-B overexpression
s seen in lymphoma cells carrying t(14:18), and it has
een demonstrated that cell lines expressing an IB  super-
epressor exhibit decreased levels of Bcl-2 protein, indicating
 role for NF-B in cells harboring this translocation. Since
roteasome inhibitors are employed in FL, a relationship
etween NF-B and the apoptotic pathways is suggested in
L [147,151]. Also, limited effects of proteasome inhibitors
ave been seen in DLBCL, whereas some evidence suggests
hat NF-B helps to define the chemotherapy-resistant post-
C B-cell lymphomas [152].
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In hematological malignancies, increased levels of TNF-
esult in poor prognosis, and this in turn heightens the risk
f MM and other cancers such as hepatocellular carcinoma,
astric carcinoma, and breast and bladder cancer. Promyelo-
ytic leukemia protein (PML) is a known molecular marker
or cancer, and since PML regulates cell growth, DNA repair,
nd cell death, patients with normal expression of PML and
53 have a better survival chance compared to patients with
oor expression of PML and P53 [153].
.  Conclusion
Multiple therapeutic targets based on proteasomal inhibi-
ion have been identified in hematological malignancies such
s MCL, NHL, Hodgkin’s lymphoma, MM, CLL, FL, ALL,
nd DLBCL. As alternatives to conventional combination
hemotherapy, proteasome inhibitors have been used to treat
ymphomas as single agents or in combination with HDAC
nhibitors or BH3 family inhibitors. Proteasome inhibitors
onsist of synthetic and natural products, and belong to five
ifferent classes based on chemical structure (A to E). It has
een shown that proteasome inhibitors enhance antiprolif-
rative, proapoptotic, antitumor, and antiangiogenic effects
f conventional therapeutic agents in many hematologi-
al malignancies. Among proteasome inhibitors, bortezomib
a class B drug) was the first to receive FDA approval
 against MCL (for patients who had received one prior
herapy) and MM (as an initial treatment). Substantial clin-
cal benefits of bortezomib treatment have been observed
n patients with MCL (relapsed or refractory). Further-
ore, bortezomib (intravenous or subcutaneous infusion)
as successful in enhancing the antitumor activities of radio-
herapy, immunotherapy, and chemotherapy, and was well
olerated with minimal added toxicities. Similarly, protea-
ome inhibitors such as CEP-18770 (oral administration),
arfilzomib (infusion), and marizomib (oral or intravenous),
nd MLN9708 (intravenous or oral) are also currently being
linically evaluated for various hematological malignan-
ies. Thus, the inhibition of tumor proteasomal activity has
roved to be highly significant in treating lymphomas and
ther malignancies, and has shown potential impact on vari-
us transcription factors including NF-B, IkB, and c-Myc.
aken together, proteasome inhibitors comprise a group of
romising therapeutics for future anti cancer therapy; they
ay be used as single agents or used in combination to
nhance the antitumor effects of conventional drugs.
Since mechanisms of proteasome inhibition are dif-
erent among the proteasome inhibitors as described
arlier, a combination therapy with multiple PIs which
re chemically different should be interesting in arresting
umorigenesis and managing lymphoma patient outcomes.
ombinations of proteasome inhibitors with novel cyto-
oxic and conventional agents are currently being evaluated
n pre-clinical and clinical trials to improve patient
esponses and outcomes. Various combinations of secondgy/Hematology 87 (2013) 306–322
eneration proteasome inhibitors such as carfilzomib, mari-
omib, MLN9708, CEP-18770, and ONYX-0912 along with
argeted agents such as heat shock protein inhibitors, histone
eacetylase inhibitors, and AKT inhibitors may also drive
ymphoma therapy in a promising direction. Bortezomib
n combination with widely used chemotherapeutic drugs
uch as dexamethasone, rituximab, ifosfamide, carboplatin,
elphalan, doxorubicin, thalidomide, lenalidomide, and
toposide is being evaluated under clinical trials for MCL,
M, WM (Waldenstrom macroglobulinemia), and other
ematological malignancies (http://www.clinicaltrials.gov/).
owever, there are challenges and limitations regarding
oxicity profiles of proteasome inhibitors when used in com-
ination therapy such as peripheral neuropathy, fatigue,
ausea, anxiety, insomnia, and transient cognitive changes.
he future of proteasome inhibition in lymphoma therapy
esides in successfully managing these challenges, improv-
ng safety and tolerability, and decreasing chemotherapy
esistance for the betterment and prolonged survival of
atients.
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